Abstract

Addus HomeCare is scheduled to report quarterly results on August 3, 2026 Post Market, with revenue, profitability, and adjusted EPS expected to improve year over year, while investors focus on margin durability and execution in key service lines.

Market Forecast

Based on the latest compiled projections, Addus HomeCare’s current quarter is expected to deliver revenue of 376.26 million US dollars, implying year-over-year growth of 8.58%. Forecast EBIT stands at 42.99 million US dollars, up 12.58% year over year, and adjusted EPS is estimated at 1.70, up 15.65% year over year. Forecast gross profit margin and net profit margin are not disclosed; the market will compare actual delivery against the company’s recent margin run-rate.

Personal Care remains the anchor of the revenue model after contributing 281.09 million US dollars last quarter; management initiatives and expected service-hour stability underpin the projected 8.58% year-over-year revenue expansion this quarter. Hospice is viewed as the most promising growth contributor within the portfolio, having generated 65.79 million US dollars last quarter and positioned to benefit from census and mix improvements; while a specific segment-level year-over-year figure is not disclosed, the company-level comparisons (revenue +8.58% YoY; EPS +15.65% YoY; EBIT +12.58% YoY) frame expectations for incremental contribution from this segment.

Last Quarter Review

In the prior quarter, Addus HomeCare reported revenue of 363.61 million US dollars, a gross profit margin of 31.87%, GAAP net profit attributable to shareholders of 25.07 million US dollars, a net profit margin of 6.89%, and adjusted EPS of 1.62, up 14.09% year over year.

A notable highlight was the 15.82% quarter-on-quarter decline in net profit, which the market interpreted as a reset against a robust year-over-year trajectory for EPS and a stable gross margin baseline. The main business mix remained concentrated in Personal Care at 281.09 million US dollars, supplemented by Hospice at 65.79 million US dollars and Home Health at 16.73 million US dollars; consolidated revenue grew 7.67% year over year.

Current Quarter Outlook

Personal Care: Volume, staffing continuity, and operating efficiency

Personal Care is the principal earnings engine by revenue contribution. The forecast for 376.26 million US dollars in total revenue and the associated 8.58% year-over-year increase imply that service hours and visit volumes in Personal Care must hold up or improve marginally, with caregiver availability and scheduling efficiency as key constraints. Against last quarter’s 31.87% gross margin and 6.89% net margin, investors will look for evidence of cost discipline in caregiver wage management, routing and shift optimization, and overtime containment to protect profitability as labor inputs scale with demand. The operational nuance this quarter is the sensitivity of margin to the cadence of wages relative to reimbursement rates and contract pricing. If labor costs trend as planned and attendance improves modestly, incremental margin could follow through in line with the EPS estimate of 1.70, which implies 15.65% year-over-year growth—a pace faster than revenue and indicative of potential operating leverage. Conversely, any disruption in case mix, authorization hours, or caregiver supply would pressure both revenue capture and margin mix, making the Personal Care delivery curve the fulcrum for whether the company meets or exceeds EPS expectations. Cash conversion in Personal Care is also a focal point, given that working-capital timing can influence reported profitability and investor reaction. Reduced claims resubmissions and stable days sales outstanding would support the EBIT estimate of 42.99 million US dollars, which is up 12.58% year over year. The market will scrutinize whether volume stability translates into proportional revenue without adverse slippage in collections or write-offs, thereby maintaining a path toward margin consistency amid growth.

Hospice: Census trajectory and fixed-cost leverage in a scaled line

Hospice continues to be positioned as the most promising segment within the company’s mix, supported by a last-quarter contribution of 65.79 million US dollars and a strategic role in enhancing blended margins. The segment’s economics rely heavily on census build, length of stay, and discipline around clinical staffing and visit intensity; even modest census gains from the prior quarter can produce disproportionate EBITDA uplift due to fixed-cost leverage. This operating dynamic aligns with the broader company forecast of year-over-year growth in both revenue and profit metrics, providing a potential cushion if Personal Care growth delivers at or near baseline. From a revenue quality standpoint, Hospice performance this quarter will be judged on stability in referral channels, discharge and recertification patterns, and retention, because these factors influence the balance of high-acuity and longer-stay patients. If favorable mix or utilization sustains, Hospice should amplify the company’s margin profile beyond the 31.87% gross margin benchmark observed last quarter, though the actual margin print will depend on case complexity and visit frequency. Notably, fixed-cost leverage in Hospice could enable incremental contribution even if the top-line improvement is not dramatic, supporting EPS outperformance potential versus the 1.70 consensus if execution is tight and costs remain controlled. The market will also examine how Hospice contributes to consolidated EBIT, which is projected to grow 12.58% year over year to 42.99 million US dollars. If Hospice contribution tracks as expected while Personal Care remains steady, the company can maintain momentum in adjusted EPS growth. Any deviation—such as uneven referral patterns, transient census headwinds, or higher-than-planned clinical staffing expense—would likely temper the upside and shift investor focus back to near-term cost containment and operational throughput.

What could move the stock: Margins versus last quarter’s baseline, QoQ normalization, and capital deployment

The stock’s reaction will be most sensitive to margin outcomes compared with the last quarter’s 31.87% gross margin and 6.89% net margin benchmarks. Management’s ability to convert the forecast revenue of 376.26 million US dollars into stable or improving margins will determine whether the 15.65% year-over-year adjusted EPS growth is realized or exceeded. Because the prior quarter saw a 15.82% sequential decline in net income, any stabilization or rebound on a quarter-over-quarter basis—paired with solid year-over-year trends—would be interpreted positively, suggesting normalization rather than a trend break. Another catalyst is the alignment between operating expense growth and revenue. If SG&A scales below revenue growth, EBIT margin should benefit, reinforcing the 42.99 million US dollars forecast for EBIT (+12.58% year over year) and validating the narrative of cost stewardship. Conversely, if wage inflation, hiring costs, or overtime outpace revenue growth, the company may deliver within the revenue range but miss on margins, which would likely pressure the shares in the immediate aftermath of the print. This sensitivity makes mix, staffing utilization, and scheduling accuracy pivotal real-time indicators for investors during the commentary and Q&A. Capital deployment and free-cash-flow signals are also potential swing factors. While the forecast does not specify cash metrics, investors will parse commentary for any intentions around incremental growth investments or integration spend that could influence near-term margin cadence. A balanced message—showing disciplined expense management and a focus on the highest-return opportunities—would support the case for sustained EPS progression beyond this quarter’s 1.70 estimate. In contrast, if the company indicates the need for elevated near-term investments without proportional revenue or margin uplift, the near-term narrative could tilt cautious despite otherwise favorable year-over-year comparisons.

Analyst Opinions

Over the last six months, collected views tilt bearish: 0% bullish versus 100% bearish within the set of identified ratings, with two Sell reiterations from a single institution. Barclays analyst Andrew Mok CFA maintained a Sell rating on Addus HomeCare with a price target of 112.00 US dollars earlier in the period and later reiterated Sell with a 102.00 US dollars target, signaling persistent skepticism on near-term upside despite year-over-year growth embedded in revenue and earnings forecasts. The sequence of Sell calls, and the reduction in the target from 112.00 to 102.00 US dollars, highlights concerns about achieving or maintaining margin expansion in the face of operating complexities. The core of the bearish stance centers on whether forecasted leverage in revenue translates into proportionate profit improvement. Addus HomeCare’s current-quarter estimates suggest revenue of 376.26 million US dollars (+8.58% YoY), EBIT of 42.99 million US dollars (+12.58% YoY), and adjusted EPS of 1.70 (+15.65% YoY). Bears argue that such step-ups may be vulnerable to wage cost pressures, uneven staffing patterns, and tight near-term operating throughput, particularly when the prior quarter’s GAAP net income declined 15.82% sequentially. Under this lens, even a modest shortfall versus EPS or EBIT expectations could reinforce the cautious narrative and validate a conservative multiple until visibility improves. A second dimension of bearish analysis focuses on the composition of growth and the durability of margins. Personal Care must scale efficiently for the company to meet the top-line target while safeguarding the gross margin near last quarter’s 31.87% level. Bears will track whether overtime hours, caregiver turnover, and training costs intrude on gross margin, which in turn would affect net profitability against the 6.89% net margin marker. Hospice, while promising, requires steady census and controlled visit intensity to deliver fixed-cost leverage; any wobble can compress contribution, blunting the forecasted 12.58% year-over-year growth in EBIT and 15.65% growth in adjusted EPS. The presence of two Sell ratings within the window reinforces the view that execution risks are top of mind in the near term. Still, even within a bearish majority, the forecasted acceleration of adjusted EPS relative to revenue implies potential for operating leverage if execution aligns. If Personal Care volumes convert cleanly and Hospice maintains a constructive census and case-mix profile, actuals could at least meet the 1.70 adjusted EPS estimate. A positive surprise on margins—relative to the last quarter’s 31.87% gross margin and 6.89% net margin—would challenge the cautious stance and could initiate recalibration of targets. However, unless the company demonstrates sustained consistency, the prevailing view remains that a measured approach to valuation is warranted, explaining why the two gathered institutional opinions reiterate Sell with targets at 112.00 and 102.00 US dollars. From an investor’s perspective, the upcoming report frames a straightforward test. The company’s guidance-implied growth trajectory appears intact: revenue expected at 376.26 million US dollars (+8.58% YoY), EBIT at 42.99 million US dollars (+12.58% YoY), and adjusted EPS at 1.70 (+15.65% YoY). To convert this into a supportive stock reaction, management must evidence controlled expense scaling and efficient conversion of service hours into realized revenue without margin slippage. The consensus among the opinions collected leans toward caution on whether all of these can be achieved simultaneously this quarter, making margin commentary and post-report trend indicators decisive for the stock’s near-term path.